Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
10.22
Dollar change
+0.26
Percentage change
2.61
%
IndexRUT P/E- EPS (ttm)-0.57 Insider Own56.81% Shs Outstand96.41M Perf Week13.56%
Market Cap986.23M Forward P/E- EPS next Y-0.32 Insider Trans1.63% Shs Float41.68M Perf Month13.30%
Income-54.37M PEG- EPS next Q-0.10 Inst Own40.66% Short Float10.21% Perf Quarter81.21%
Sales0.03M P/S32874.33 EPS this Y-17.19% Inst Trans15.48% Short Ratio7.00 Perf Half Y180.77%
Book/sh2.39 P/B4.27 EPS next Y51.72% ROA- Short Interest4.25M Perf Year53.45%
Cash/sh2.37 P/C4.32 EPS next 5Y- ROE- 52W Range2.55 - 10.20 Perf YTD86.50%
Dividend Est.- P/FCF- EPS past 5Y-1.44% ROI-23.56% 52W High0.20% Beta0.81
Dividend TTM- Quick Ratio96.85 Sales past 5Y-34.76% Gross Margin-143.33% 52W Low300.78% ATR (14)0.58
Dividend Ex-Date- Current Ratio96.85 EPS Y/Y TTM76.45% Oper. Margin-225066.67% RSI (14)69.52 Volatility8.41% 6.19%
Employees26 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-181216.67% Recom1.00 Target Price19.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q85.23% Payout- Rel Volume2.70 Prev Close9.96
Sales Surprise- EPS Surprise49.05% Sales Q/Q- EarningsMar 21 AMC Avg Volume607.99K Price10.22
SMA2014.77% SMA5032.16% SMA20067.12% Trades Volume1,644,589 Change2.61%
Date Action Analyst Rating Change Price Target Change
Mar-05-24Upgrade Leerink Partners Market Perform → Outperform $6 → $18
Feb-20-24Upgrade William Blair Mkt Perform → Outperform
Sep-20-23Downgrade William Blair Outperform → Mkt Perform
Jan-31-23Initiated Wedbush Outperform $10
Jan-03-23Initiated William Blair Outperform $17
Dec-13-22Initiated SVB Leerink Outperform $14
Mar-26-24 08:50AM
Mar-21-24 10:53PM
05:33PM
04:05PM
Mar-15-24 06:00AM
04:05PM Loading…
Mar-07-24 04:05PM
Mar-06-24 09:01AM
Feb-26-24 09:01AM
Feb-22-24 09:01AM
Feb-20-24 09:01AM
Feb-05-24 09:01AM
Nov-09-23 04:00PM
11:02AM
Oct-06-23 09:03AM
Oct-03-23 09:03AM
03:01AM Loading…
03:01AM
Sep-29-23 07:50PM
01:39PM
10:00AM
10:00AM
Sep-21-23 12:28PM
10:43AM
06:28AM
Sep-20-23 12:42PM
10:31AM
10:26AM
09:49AM
06:13AM
Sep-19-23 10:49PM
Sep-08-23 07:10PM
04:00PM Loading…
Aug-10-23 04:00PM
Jun-20-23 08:00AM
May-15-23 02:11PM
09:00AM
May-12-23 11:51AM
May-11-23 07:01PM
May-09-23 09:10AM
Apr-21-23 10:05AM
Mar-28-23 09:39AM
Mar-25-23 09:10AM
Mar-23-23 04:01PM
Mar-22-23 06:19AM
Feb-23-23 04:01PM
Feb-22-23 04:05PM
Feb-09-23 06:30AM
05:43AM
Nov-10-22 08:00AM
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorMar 27 '24Buy9.79505,9544,953,2909,958,073Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 26 '24Buy9.55457,7454,371,4659,452,119Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 25 '24Buy9.06437,6003,964,6568,994,374Mar 27 07:37 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 25 '24Sale9.1295,267869,1881,697,447Mar 26 06:47 PM
Lowenthal Richard EPRESIDENT AND CEOMar 25 '24Sale9.1295,267869,1881,697,447Mar 26 06:48 PM
Lowenthal Richard EPRESIDENT AND CEOMar 22 '24Sale9.022,34321,1351,745,082Mar 26 06:48 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 22 '24Sale9.022,34321,1351,745,082Mar 26 06:47 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 21 '24Sale9.004724,2481,746,099Mar 21 09:50 PM
Lowenthal Richard EPRESIDENT AND CEOMar 21 '24Sale9.004724,2481,746,099Mar 21 09:51 PM
Lowenthal Richard EPRESIDENT AND CEOMar 19 '24Sale9.031,91817,3241,746,471Mar 21 09:51 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 19 '24Sale9.031,91817,3241,746,471Mar 21 09:50 PM
Lowenthal Richard EPRESIDENT AND CEOMar 15 '24Sale9.1496,756884,4851,696,494Mar 15 07:55 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 15 '24Sale9.1496,756884,4851,696,494Mar 15 07:52 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 14 '24Sale9.004443,9961,744,789Mar 15 07:52 PM
Lowenthal Richard EPRESIDENT AND CEOMar 14 '24Sale9.004443,9961,744,789Mar 15 07:55 PM
Lowenthal Richard EPRESIDENT AND CEOMar 13 '24Sale9.002,80025,2001,744,994Mar 15 07:55 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERMar 13 '24Sale9.002,80025,2001,744,994Mar 15 07:52 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERFeb 29 '24Sale9.023,78234,1011,746,494Mar 01 08:21 PM
Lowenthal Richard EPRESIDENT AND CEOFeb 29 '24Sale9.023,78234,1011,746,494Mar 01 08:17 PM
Lowenthal Richard EPRESIDENT AND CEOFeb 28 '24Sale9.0298,778891,0611,747,294Feb 28 09:04 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERFeb 28 '24Sale9.0298,778891,0611,747,294Feb 28 09:08 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERFeb 26 '24Sale9.017006,3071,772,750Feb 28 09:08 PM
Lowenthal Richard EPRESIDENT AND CEOFeb 26 '24Sale9.017006,3071,772,750Feb 28 09:04 PM
Fitzpatrick Alexander AChief Legal OfficerSep 29 '23Buy3.7846,258174,99489,227Oct 02 04:23 PM
Fitzpatrick Alexander AChief Legal OfficerSep 28 '23Buy3.6240,000144,96042,969Oct 02 04:23 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 21 '23Buy3.032,700,0008,183,5268,556,774Sep 25 04:30 PM
Shawver LauraDirectorSep 01 '23Option Exercise1.27100,000127,000310,346Sep 05 08:04 PM
Shawver LauraDirectorSep 01 '23Sale7.71100,000770,520210,346Sep 05 08:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorAug 29 '23Buy6.203,750,00023,250,0005,856,774Aug 31 05:26 PM
ORBIMED ADVISORS LLCDirectorAug 29 '23Buy6.20500,0003,100,0008,019,187Aug 31 05:26 PM
Thompson Peter A.DirectorAug 29 '23Buy6.20500,0003,100,0008,019,187Aug 31 05:18 PM
Shawver LauraDirectorAug 04 '23Option Exercise1.2718,89723,999229,243Aug 07 05:05 PM
Shawver LauraDirectorAug 04 '23Sale7.0618,897133,471210,346Aug 07 05:05 PM
Shawver LauraDirectorAug 03 '23Option Exercise1.2726,10733,156236,453Aug 07 05:05 PM
Shawver LauraDirectorAug 03 '23Sale7.0126,107183,018210,346Aug 07 05:05 PM
Shawver LauraDirectorAug 02 '23Option Exercise1.2736,28146,077246,627Aug 03 06:03 PM
Shawver LauraDirectorAug 02 '23Sale7.0936,281257,265210,346Aug 03 06:03 PM
Shawver LauraDirectorAug 01 '23Option Exercise1.2718,71523,768229,061Aug 03 06:03 PM
Shawver LauraDirectorAug 01 '23Sale7.1918,715134,576210,346Aug 03 06:03 PM
Shawver LauraDirectorJul 07 '23Option Exercise1.278,85811,250219,204Jul 07 08:16 PM
Shawver LauraDirectorJul 07 '23Sale6.368,85856,372210,346Jul 07 08:16 PM
Shawver LauraDirectorJul 06 '23Option Exercise1.2733,51042,558243,856Jul 06 08:55 PM
Shawver LauraDirectorJul 06 '23Sale6.3433,510212,554210,346Jul 06 08:55 PM
Shawver LauraDirectorJul 05 '23Option Exercise1.2731,11239,512241,458Jul 06 08:55 PM
Shawver LauraDirectorJul 05 '23Sale6.4131,112199,552210,346Jul 06 08:55 PM
Shawver LauraDirectorJul 03 '23Option Exercise1.2726,52033,680236,866Jul 06 08:55 PM
Shawver LauraDirectorJul 03 '23Sale6.7226,520178,347210,346Jul 06 08:55 PM
Shawver LauraDirectorJun 02 '23Option Exercise1.2726,94134,215237,287Jun 02 07:48 PM
Shawver LauraDirectorJun 02 '23Sale6.9526,941187,240210,346Jun 02 07:48 PM
Shawver LauraDirectorJun 01 '23Option Exercise1.2773,05992,785283,405Jun 02 07:48 PM
Shawver LauraDirectorJun 01 '23Sale6.8073,059496,801210,346Jun 02 07:48 PM
Shawver LauraDirectorMay 09 '23Option Exercise1.2742,90054,483253,246May 10 04:53 PM
Shawver LauraDirectorMay 09 '23Sale5.3142,900227,799210,346May 10 04:53 PM
Shawver LauraDirectorMay 08 '23Option Exercise1.2757,10072,517267,446May 10 04:53 PM
Shawver LauraDirectorMay 08 '23Sale6.1657,100351,736210,346May 10 04:53 PM